Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01961063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started2015-12-31
View on ClinicalTrials.gov ↗
This pilot clinical trial studies gene therapy after frontline chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). Placing genes for anti-human immunodeficiency virus (HIV) ribonucleic acid (RNA) into stem/progenitor cells may make the body build an immune response to AIDS. Giving the chemotherapy drug busulfan before gene therapy can help gene-modified cells engraft and work better.

Amendment history 2 changes detected by DataLookout

2026-09-02
Primary completion pushed: 2026-08-05 → 2027-07-06
2026-09-02
Completion pushed: 2026-08-05 → 2027-07-06
Trial Details
NCT Number NCT01961063
Lead Sponsor City of Hope Medical Center
Conditions AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma, HIV Infection
Enrollment 3 participants
Start Date 2015-12-31
Primary Completion 2027-07-06 (estimated)
Study Completion 2027-07-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-01